SAR1B contributes to progression of lung cancer via enhancing cell proliferation and migration
preprint
OA: closed
CC-BY-4.0
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide with increasing incidence. Secretion associated ras related GTPase 1B (SAR1B) encode a protein that responsible for protein transport from the endoplasmic reticulum to the Golgi apparatus. However, the exact involvement of SAR1B in lung cancer is not yet fully understood. In this study, clinical human lung cancer tissues and normal para-carcinoma tissues were analysed to identify the expression of SAR1B. We additionally evaluated the impact of SAR1B on malignant features of lung cancer cells both in vitro and in vivo by developing stable knockdown cell models for SAR1B. Our results revealed that SAR1B was highly expressed in lung cancer tissues, particularly in those that had advanced stages of the lung cancer, as compared with normal para-carcinoma tissues. Concomitantly, overexpression of SAR1Bwas associated with a shorter survival for patients with lung cancer. Moreover, SAR1B knockdown was shown to have a significant impact on suppressing the proliferation and migration of lung cancer cells, while promoting cell apoptosis. Our in vivo experiments further confirmed the the indispensable role of SAR1B on tumorigenesis. In conclusion, these results demonstrated the promoting role of SAR1B in proliferation and migration of lung cancer cells. SAR1B shows promise as a novel biomarker for lung cancer progression and has potential for use as a therapeutic target for patients with lung cancer.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0